Advertisement
U.S. Markets close in 6 hrs 13 mins

Vicore Pharma Holding AB (publ) (6Y4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.6120-0.0210 (-3.32%)
As of 08:07AM CET. Market open.

Vicore Pharma Holding AB (publ)

Kornhamnstorg 53
Stockholm 111 27
Sweden
46 3 17 88 05 60
https://www.vicorepharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 29

Key Executives

NameTitlePayExercisedYear Born
Mr. Ahmed S. Mousa J.D.Chief Executive Officer5.6MN/A1985
Mr. Hans Jeppsson Ph.D.Chief Financial OfficerN/AN/AN/A
Mr. Mikael NygårdVice President of Operations & Corporate StrategyN/AN/AN/A
Dr. Johan Raud Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Nina CarlenChief Administrative OfficerN/AN/AN/A
Ms. Megan RichardsVP of Investor Relations, Communications & Portfolio StrategyN/AN/AN/A
Ms. Jessica ShullHead of Digital Therapeutics & Director of Digital InnovationN/AN/AN/A
Ms. Asa MagnussonChief Engagement & Commercial OfficerN/AN/A1966
Prof. Bertil Lindmark M.D., Ph.D.Chief Medical OfficerN/AN/A1955
Mr. Jimmie HofmanVice President of Business DevelopmentN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. Vicore Pharma Holding AB (publ) has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Corporate Governance

Vicore Pharma Holding AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.